Xtrackers MSCI EAFE ESG Leaders Equity ETF
EASG - ETF AI Analysis
Top Page
Xtrackers MSCI EAFE ESG Leaders Equity ETF (EASG)
EASG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 66.70M
- Region
- Developed Markets
- Expense Ratio
- 0.03%
- Beta
- 0.77
- Issuer
- Xtrackers
- Inception Date
- Sep 06, 2018
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- Bloomberg Developed Markets ex US Core Markets Index - USD - Benchmark TR Net
EASG Summary
EASG is the Xtrackers MSCI EAFE ESG Leaders Equity ETF, which follows the MSCI EAFE ESG Leaders index. It invests in large companies from developed markets outside North America, such as Europe, Japan, and Australia, that score well on environmental, social, and governance (ESG) standards. Well-known holdings include ASML Holding and HSBC. Someone might invest in this ETF to diversify their portfolio internationally while focusing on companies that aim to act responsibly and sustainably. A key risk is that the fund can still rise and fall with global stock markets, especially outside the U.S.
How much will it cost me?
The Xtrackers MSCI EAFE ESG Leaders Equity ETF (Ticker: EASG) has an expense ratio of 0.14%, meaning you’ll pay $1.40 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index of ESG-focused companies rather than relying on active stock picking.
What would affect this ETF?
The EASG ETF could benefit from growing global interest in ESG-focused investments and sustainability trends, as well as potential economic growth in developed markets outside North America. However, it may face challenges from regulatory changes affecting ESG criteria, economic slowdowns in Europe or Asia, or sector-specific risks in industries like financials and technology, which have significant weight in the fund.
EASG Top 10 Holdings
EASG’s story is driven by a handful of global heavyweights. ASML and Tokyo Electron are the fund’s turbochargers, with rising semiconductor momentum giving performance a strong lift. On the financial side, HSBC and Allianz are steady to rising, helping balance out the picture, while Commonwealth Bank of Australia has been lagging and quietly weighing on returns. Health care is a mixed bag, with Novartis holding firm but AstraZeneca losing steam. Overall, the ETF leans into developed markets outside North America, with a clear tilt toward European and Asian leaders.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Samsung Electronics | 3.76% | $2.52M | KRW 1319.90T | 100.39% | ―― | |
| SK hynix Inc. | 2.60% | $1.75M | KRW 886.30T | 98.69% | ―― | |
| ASML Holding NV | 2.51% | $1.68M | EUR 511.40B | 51.88% | 76Outperform | |
| HSBC Holdings | 1.31% | $877.40K | GBP 231.98B | 20.93% | 80Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Shell (UK) | 1.06% | $707.80K | GBP 210.62B | 30.08% | 73Outperform | |
| Novartis AG | 1.04% | $695.60K | CHF 245.40B | 26.78% | 80Outperform | |
| Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Nestlé SA | 0.91% | $611.94K | CHF 225.64B | 8.18% | 71Outperform |
EASG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EASG, the sentiment is Neutral. The current price of 38.42 is below the 20-day moving average (MA) of 38.65, below the 50-day MA of 38.74, and above the 200-day MA of 36.98, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 47.45 is Neutral, neither overbought nor oversold. The STOCH value of 72.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EASG.
EASG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $38.42 | $41.00(6.70% Upside) | $66.70M | 0.03% | 61Neutral | |
| $39.79 | $43.51(9.36% Upside) | $55.65M | 0.24% | 59Neutral | |
| $35.27 | $38.02(7.78% Upside) | $54.43M | 0.12% | 68Neutral | |
| $36.26 | $40.28(11.10% Upside) | $35.36M | 0.48% | 70Outperform | |
| $27.42 | $32.21(17.48% Upside) | $20.53M | 0.42% | 66Neutral | |
| $30.80 | $37.51(21.76% Upside) | $18.53M | 0.55% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EASG | Xtrackers MSCI EAFE ESG Leaders Equity ETF | 38.42 | 4.87 | 14.52% | |
| DEEF | Xtrackers FTSE Developed ex US Multifactor ETF | 39.78 | 5.88 | 17.34% | |
| QLVD | FlexShares Developed Markets ex-US Quality Low Volatility Index Fund | 35.27 | 5.08 | 16.82% | |
| OEFA | O'Shares International Developed Quality Dividend ETF | 36.26 | 4.38 | 13.76% | |
| RWIN | Rayliant NxtGen Multifactor International Equity ETF | 27.42 | 1.70 | 6.61% | |
| FFDI | Fidelity Fundamental Developed International ETF | 30.80 | 1.94 | 6.73% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
